Congress blocks China from buying Americans' genetic data
H.R. 2286 — American Genetic Privacy Act of 2025 · Filed by Tim Burchett (R-TN) · 4 cosponsors · Introduced Mar 24, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the sale or disclosure of genetic information collected by commercial DNA testing services (like ancestry kits) to China or Chinese-controlled entities. It treats violations as unfair trade practices enforceable by the Federal Trade Commission, with penalties under existing FTC authority.
Why we flagged it
The bill's operative mechanism is a targeted prohibition on genetic-data transfer to a named foreign power, enforced through existing consumer-protection law. It is a national-security measure framed as privacy protection, not a broad privacy overhaul.
What the text implies
- The bill does not restrict domestic data sales or sharing among U.S. companies, meaning genetic data can still be sold to U.S. third parties, brokers, or advertisers without restriction.
- Enforcement relies on FTC's existing unfair-practice authority, which may create gaps if Chinese acquisition occurs through intermediaries, shell companies, or indirect ownership structures not clearly 'under the influence, control, or ownership' of China.
The full analysis lists 4 implications of this text.
Who stands to gain
commercial DNA testing services (23andMe, Ancestry, MyHeritage, etc.); U.S.-based genetic data brokers and analytics firms